R Squared Ltd Acquires New Holdings in ABIVAX Société Anonyme (NASDAQ:ABVX)

R Squared Ltd bought a new stake in ABIVAX Société Anonyme (NASDAQ:ABVX) during the fourth quarter, Holdings Channel.com reports. The fund bought 4,950 shares of the company’s stock, valued at approximately $36,000.

Several other institutional investors also recently modified their holdings of ABVX. abrdn plc grew its holdings in shares of ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Point72 Asset Management L.P. raised its position in ABIVAX Société Anonyme by 28.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after purchasing an additional 119,300 shares during the last quarter. Walleye Capital LLC raised its position in ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the last quarter. Finally, GAMMA Investing LLC bought a new stake in shares of ABIVAX Société Anonyme during the fourth quarter worth $29,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ABVX shares. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $38.67.

ABIVAX Société Anonyme Trading Down 0.5 %

ABVX opened at $5.94 on Tuesday. ABIVAX Société Anonyme has a 52-week low of $5.49 and a 52-week high of $17.02. The business’s 50-day simple moving average is $7.23 and its 200 day simple moving average is $9.62.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.